Randomized phase III study of intravenous (IV) paclitaxel and cisplatin vs. IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172).

Trial ID # GOG-172
Phase III
Drug Class Chemotherapy, Chemotherapy
Drug Name Cisplatin, Paclitaxel
Alternate Drug Names CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin , Blastolem , Briplatin , Cisplatyl , Citoplatino , Citosin , Lederplatin , Metaplatin , Neoplatin , Placis, Platamine , Platiblastin , Platiblastin-S , Platinex , Platiran, Platistin, Platosin, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL
Drugs in Trial Cisplatin, Paclitaxel
Eligible Participant

Newly diagnosed stage III ovarian cancer (optimally debulked)

Patients Enrolled


Therapy Setting


Study Design



PFS, OS, evaluated per RECIST


CisPt+Pac (IV) vs CisPt+Pac (IP):

PFS: 18.3 vs 23.8 months, RR: 0.80 (0.64-1.00, p=0.05)
OS: 49.7 vs 65.6 months, RR: 0.75 (0.58-0.97, p=0.03)

Clinically Significant Adverse Events

CisPt+Pac (IV) vs CisPt+Pac (IP):
Grade 3-4 AE: leukopenia (64 vs 76%), GI events (24 vs 46%), neurologic events (9 vs 19%), infection (6 vs 16%), fatigue (4 vs 18%), metabolic events (7 vs 27%), decreased platelet counts (4 vs 12%), pain (1 vs 11%)


PFS and OS increased with IP treatment in optimally debulked stage III patients, but IP had more severe AEs


Armstrong DK et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. NEJM (2006) 354(1):34-43

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.